Alder BioPharmaceuticals prices upsized IPO at $10, well below the range

By
A A A

Alder BioPharmaceuticals, which is developing antibodies to prevent migraine and treat rheumatoid arthritis, raised $80 million by offering 8.0 million shares at $10, below its proposed $13 to $15 range. Alder BioPharmaceuticals will list on the NASDAQ under the symbol ALDR. Credit Suisse and Leerink Partners acted as joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks: ALDR

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Visualizing Healthcare MG
Visualizing Healthcare MG           
Power on/Power Off IPC
Power on/Power Off IPC              
Spot the Dropout RRC
Spot the Dropout RRC                
Power on/Power Off
Power on/Power Off                  

Stocks

Referenced

Most Active by Volume

10,238,018
  • $16.225 ▼ 0.83%
9,021,445
  • $112.58 ▼ 0.63%
8,243,993
  • $10.33 ▼ 1.62%
8,130,190
  • $10.44 ▲ 1.36%
8,007,966
  • $27.54 ▲ 2.65%
7,895,466
  • $2.60 ▲ 8.79%
7,248,307
  • $13.6195 ▼ 0.88%
7,124,466
  • $104.75 ▼ 0.82%
As of 8/31/2015, 10:17 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com